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ABSTRACT		A	new,	simple,	precise,	accurate	and	reproducible	RP-HPLC	method	for	Simultaneous	estimation	of	bulk	and	pharmaceutical	formulations.	Separation	of	Guaifenesin	and	Dextromethorphan	was	successfully	achieve	THERMO,	 C18,	 250X4.6mm,	 5µm	 or	 equivalent	 in	 an	 isocratic	 mode	 utilizing	 0.1M	 KH2PO4:	 Methanol	(60:40)	at	a	flow	rate	of	1.0ml/min	and	eluate	was	monitored	at	280nm,	with	a	retention	time	of	3.259	and	4.164	minutes	for	Guaifenesin	and	Dextromethorphan	respectively.	The	method	was	validated	and	there	response	was	found	to	be	linear	in	the	drug	concentration	range	of	50µg/ml	to150	µg/ml	for	Guaifenesin	and	50µg/ml	to150	µg/ml	for	Dextromethorphan.	The	values	of	the	correlation	coefficient	were	found	to	0.999	for	Guaifenesin	and	1for	Dextromethorphan.	respectively.	The	LOD	and	LOQ	for	Guaifenesin	were	found	to	be	0.597	and	1.991	respectively.	The	LOD	and	LOQ	for	Dextromethorphan	were	found	to	be	0.1072	and	0.3572	respectively.	This	method	was	found	to	be	good	percentage	recovery	for	were	found	to	be	99	and	100	respectively	indicates	that	the	proposed	method	is	highly	accurate.	The	specificity	of	the	method	shows	good	correlation	between	retention	times	of	standard	with	the	sample	so,	the	method	specifically	determines	 the	 analyte	 in	 the	 sample	without	 interference	 from	 excipients	 of	 tablet	 dosage	 forms.	 The	method	was	extensively	validated	according	to	ICH	guidelines	for	Linearity,	Accuracy,	Precision,	Specificity	and	Robustness.	
Keywords:	Guaifenesin;	Dextromethorphan;	RP-HPLC.	
	INTRODUCTION	In	order	to	develop	a	simple,	reliable	and	an	accurate	method	development	and	validation	of	Gauifenes	 in	
and	 Dextromethorphan	 in	 pharmaceutical	 dosage	form	by	Reverse	phase	HPLC	and	validate	the	method	for	its	repeatability	and	reproducibility	Guaifenesin	 is	 thought	 to	 act	 as	 an	 expectorant	 by	increasing	the	volume	and	reducing	the	viscosity	of	secretions	in	the	trachea	and	bronchi.	It	has	been	said	to	 aid	 in	 the	 flow	 of	 respiratory	 tract	 secretions,	allowing	 ciliary	 movement	 to	 carry	 the	 loosened	secretions	 upward	 toward	 the	 pharynx.[8]	 Thus,	 it	may	 increase	 the	 efficiency	 of	 the	 cough	 reflex	 and	facilitate	removal	of	the	secretions.	Guaifenesin	 is	 an	 expectorant	 commonly	 used	 in	performance	horses	to	aid	in	the	clearance	of	mucus	from	 the	 airways.	 Guaifenesin	 is	 also	 a	 centrally	acting	 skeletal	 muscle	 relaxant	 and	 as	 such	 is	 a	prohibited	drug	with	withdrawal	necessary	prior	to	competition.	To	the	authors'	knowledge,	there	are	no	reports	in	the	literature	describing	single	or	multiple	oral	 administrations	 of	 guaifenesin	 in	 the	 horse	 to	determine	 a	 regulatory	 threshold	 and	 related	withdrawal	 time.[9]	 Therefore,	 the	 objective	 of	 the	current	study	was	to	describe	the	pharmacokinetics	of	guaifenesin	following	oral	administration	in	order	to	provide	data	upon	which	 appropriate	 regulatory	
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recommendations	can	be	established.	Nine	exercised	Thoroughbred	 horses	 were	 administered	 2	 g	 of	guaifenesin	orally	BID	for	a	total	of	five	doses.	Blood	samples	 were	 collected	 immediately	 prior	 to	 drug	administration	 and	 at	 various	 times	 post	administration.	 Serum	 guaifenesin	 concentrations	were	 determined	 and	 pharmacokinetic	 parameters	calculated.	Guaifenesin	was	rapidly	absorbed	(Tmax	of	15	min)	 following	oral	administration.	The	Cmax	was	681.3	±	323.8	ng/mL	and	1080	±	732.8	following	the	 first	 and	 last	 dose,	 respectively.	 The	 serum	elimination	half-life	was	2.62	±	1.24	h.	Average	serum	guaifenesin	concentrations	remained	above	the	LOQ	of	the	assay	(0.5	ng/mL)	by	48	h	post	administration	of	the	final	dose	in	3	of	9	horses.[18]	At	 therapeutic	 doses,	 dextromethorphan	 acts	centrally	 (meaning	 that	 it	 acts	 on	 the	 brain)	 as	opposed	 to	 locally	 (on	 the	 respiratory	 tract).	 It	elevates	 the	 threshold	 for	 coughing,	 without	inhibiting	 ciliary	 activity.	 Dextromethorphan	 is	rapidly	absorbed	from	the	gastrointestinal	tract	and	converted	into	the	active	metabolite	dextrorphan	in	the	 liver	 by	 the	 cytochrome	P450	 enzyme	CYP2D6.	The	average	dose	necessary	for	effective	antitussive	therapy	is	between	10	and	45	mg,	depending	on	the	individual.	The	International	Society	for	the	Study	of	Cough	 recommends	 "an	 adequate	 first	 dose	 of	medication	 is	60	mg	 in	 the	adult	and	repeat	dosing	should	 be	 infrequent	 rather	 than	 the	 qds	recommended."[27]	DXM	has	an	elimination	half-life	of	approximately	4	hours	 in	 individuals	 with	 an	 extensive	metabolizer	phenotype;	 this	 is	 increased	 to	 approximately	 13	hours	 when	 DXM	 is	 given	 in	 combination	 with	quinidine.[20]	 The	 duration	 of	 action	 after	 oral	administration	 is	 about	 three	 to	 eight	 hours	 for	dextromethorphan	 hydrobromide,	 and	 10	 to	 12	hours	 for	dextromethorphan	polistirex.	Around	one	in	 10	 of	 the	 Caucasian	 population	 has	 little	 or	 no	CYP2D6	 enzyme	 activity,	 leading	 to	 long-lived	 high	drug	levels	
 
Figure 1: Structure of Guaifenesin 
 
Figure 2: Structure of Dextromethorphan	
MATERIALS	AND	METHODS		
Chemical	and	Reagents		Guaifenesin	 and	 Dextromethorphan	 were	 kindly	gifted	 by	 Pvt	 Ltd,	 Hyderabad	 certified	 to	 contain	99.9%	and	99.7%	purity	respectively.	The	drugs	were	used	 without	 further	 purification.	 All	 the	 solvents	used	in	analysis	were	of	HPLC	grade.	
HPLC	method		
Instrument		Waters	HPLC,	Model:	Waters	2695,	Photo	diode	array	detector	(PDA),	with	an	automated	sample	 injector.	The	 output	 signal	 was	 monitored	 and	 integrated	using	 Empower	 2	 software.	 THERMO,	 C18,	 250X	4.6mm,	5µm,column	was	used	for	separations.	
Optimized	Chromatographic	conditions		Mobile	Phase:	KH2PO4:	Methanol	(60:40)	Column	:	THERMO,	C18,	25cmx4.6mm,	5µm	Flow	Rate	:	1.0ml/Min	Temperature	:	25˚C	Volume	:	10µl	 	Run	time	:	10min	Detector	:	280		
Preparation	of	Mobile	Phase	Transfer	 1000ml	 of	 HPLC	 water	 into1000ml	 of	beaker	 add	 0.1M	 KH2PO4.	 Transfer	 the	 above	prepared	KH2PO4	buffer	and	Methanol	is	mixed	in	the	proportion	of	(60:40).	They	are	mixed	and	sonicated	for	20min.	
Preparation	 of	 the	 Guaifenesn	 and	
Dextromethorphan	standard	and	sample	solution	
Standard	Solution	Preparation	Accurately	weigh	and	transfer	400.00	of	Guaifenesin	and	 20.00	 Dextromethorphan	 100ml	 of	 volumetric	flask	and	add	10ml	of	Methanol	and	sonicate	10min	(or)	shake	5min	and	make	with	water.	Transfers	the	above	 solution	 into	 1ml	 into	 10ml	 volumetric	 flask	dilute	to	volume	with	water.	
Preparation	of	sample	stock	solution	Commercially	available	20	tablets	ware	weighed	and	powdered	the	powdered	equivalent	to	the	980.00	mg	of	 Guaifenesin	 and	 Dextromethorphan	 of	 active	ingredients	were	transfer	into	a	100ml	of	volumetric	flask	and	add	10ml	of	Methanol	and	sonicate	20min	(or)	shake	10min	and	makeup	with	water.	Transfers	above	solution	1ml	into	10ml	of	the	volumetric	flask	dilute	 the	 volume	with	Methanol.	 And	 the	 solution	was	 filtered	 through	 0.45μm	 filter	 before	 injecting	into	HPLC	system.	
Recovery	studies	
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To	 check	 the	 accuracy	 of	 sample	 by	 the	 developed	methods	and	to	study	the	interference	of	formulation	additives,	 analytical	 recovery	 experiments	 were	carried	out	by	standard	addition	method	at	50,	100	and	150%	level.	From	the	total	amount	of	drug	found,	the	percentage	recovery	was	calculated.		
RESULTS	AND	DISCUSSION	
HPLC	Method	Validation	As	 per	 the	 ICH	 guidelines,	 the	 method	 validation	parameters	 checked	 were	 linearity,	 accuracy,	Specificity,	 precision,	 limit	 of	 detection,	 limit	 of	quantitation	
Specificity	Solution	of	standard,	sample,	blank	and	placebo	were	prepared	as	per	test	procedure	and	injected	into	the	HPLC	system.		
Acceptance	criteria:	Chromatogram	of	standard	and	sample	should	be	identical	with	near	Retention	time.	
Blank	 interference:	 A	 study	 to	 establish	 the	interference	 of	 blank	 was	 conducted.	 Diluent	 was	injected	into	HPLC	system	as	per	the	test	procedure.	
Acceptance	criteria:	Chromatogram	of	blank	should	not	 show	any	peak	at	 the	 retention	 time	of	 analyte	peak.	 There	 is	 no	 interference	 due	 to	 blank	 at	 the	retention	 time	 of	 analyte.	 Hence	 the	 method	 is	specific.	
Linearity	Prepare	a	series	of	standard	solutions	and	inject	into	HPLC	system.	Plot	the	graph	of	standard	versus	the	actual	 concentration	 in	 µg/ml	 and	 determine	 the	coefficient	 of	 correlation	 and	 basis	 for	 100%	response.	
Acceptance	criteria:	Linearity	regression	coefficient	of	average	peak	area	response	of	replicate	injections	plotted	against	 respective	 concentration	 should	not	be	 less	 than	 0.999.	 The	 %	 y-intercept	 as	 obtained	from	 the	 linearity	 data	 (without	 extrapolation	through	origin	0,	0)	should	be	within	±2.0.	
 
Figure 3: Linearity plot of Guaifenesin 
Table 1: Linearity data for Dextromethorphan 
S.no Conc (μg/ml) RT Area 
1 50 3.226 1865913 
2 75 3.234 2802714 
3 100 3.238 3737900 
4 125 3.243 4676782 
5 150 3.246 5609376 
Correlation coefficient (r2)  0.999 
 
Figure 4: Linearity data of Dextromethorphan 
Table 2: Linearity data of Dextromethorphan 
S.no Conc(μg/ml) RT Area 
1 50 4.078 662944 
2 75 4.086 9933167 
3 100 4.095 1328163 
4 125 4.099 1651197 
5 150 4.098 1981291 
Correlation coefficient (r2)  1.0 
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S.no Conc (μg/ml) RT Area 
1 50 3.226 1865913 
2 75 3.234 2802714 
3 100 3.238 3737900 
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5 150 3.246 5609376 
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Table 4: Linearity data for Dextromethorphan 
S.no Conc (μg/ml) RT Area 
1 50 4.078 662944 
2 75 4.086 9933167 
3 100 4.095 1328163 
4 125 4.099 1651197 
5 150 4.098 1981291 
Correlation coefficient (r2) 1.0 
Statistical	 Evaluation:	 A	 graph	 between	 the	concentration	 and	 the	 average	 area	 was	 plotted.	Points	for	linearity	were	observed.	Using	the	method	of	 least	squares,	a	 line	of	best	 fit	was	taken	and	the	correlation	 Coefficient,	 slope	 and,	 y-intercept	 were	calculated.		
Precision	
Preparation	 of	 sample:	 Transfer	 the	 980mg	 of	sample	into	a	100ml	of	volume	at	flask	and	add	10ml	of	 Methanol	 and	 sonicate	 20min	 and	makeup	 with	methanol.	Transfer	the	above	solution	into	1ml	into	10ml	volume	metric	 flask	dilute	to	the	volume	with	water.	
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The	 method	 precision	 parameters	 were	 evaluated	from	sample	chromatograms	obtained,	by	calculating	the	%	RSD	of	peek	areas	from	6	replicate	injections.	
Table 5: Precision data for Guaifenesin 
S.no RT Area %Assay 
Injection1 3.250 3739051 100 
Injection2 3.250 3739650 100 
Injection3 3.242 3732973 99 
Injection4 3.242 3732125 99 
Injection5 3.246 3737009 100 
Injection6 3.243 3735485 100 
Mean   100 
Std. Dev.   0.8 
% RSD   0.8 
Acceptance	 criteria:	 The	 injection	 reproducibility	requirements	are	met	if	the	%RSD	for	peak	areas	is	not	more	than	2.0	and	for	retention	times	is	not	more	than	2.0.	
Table 6: Precision data for Dextromethorphan 
S.no RT Area %Assay 
Injection 1 4.134 1322868 100 
Injection 2 4.132 1326738 100 
Injection 3 4.116 1321671 100 
Injection 4 4.118 1322735 100 
Injection 5 4.122 1321325 100 
Injection 6 4.113 1320900 100 
Mean   100 
Std. Dev.   0.16 
%RSD   0.16 
Recovery/accuracy	Recovery	 study	 can	 be	 performed	 in	 the	concentration	 range	 of	 80%	 to	 120%	 of	 the	 target	concentration	of	the	test.	Minimum	3	concentrations	are	recommended.	
Acceptance	 criteria:	 The	 average	 percentage	recovery	 was	 between	 98-102%	 and	 Relative	standard	deviation	of	these	recovery	concentrations	was	less	than	2%.	
Table 7: Accuracy data for Guaifenesin 
S.NO Accuracy Level 
Injec-
tion 
Sample 
area RT 
1 50% 
1 1866611 3.234 
2 1865356 3.233 
3 1865316 3.233 
2 100% 
1 3734210 3.244 
2 3738762 3.240 
3 3739706 3.241 
3 150% 
1 5607485 3.244 
2 5601456 3.248 
3 5605099 3.248 
Table 8: Accuracy data for Dextromethorphan 
S.NO Accuracy level 
Injec-
tion 
Sample 
area RT 
1  50% 
1 662941 4.102 
2 662147 4.099 
 3 662043 4.095 
2 100% 
1 1325072 4.105 
2 1326464 4.100 
3 1326207 4.099 
3 150% 
1 1980940 4.102 
2 1980145 4.103 
3 1982320 4.105 
Limit	of	detection	The	 sensitivity	 of	measurement	 of	 Guaifenesin	 and	Dextromethorphan	by	use	of	proposed	method	was	estimated	 in	 terms	 of	 the	 limit	 of	 detection	 (LOD).	The	LOD	was	calculated	by	the	use	of	signal	to	noise	ratio.	 In	order	 to	estimate	 the	LOD	value,	 the	blank	sample	was	 injected	six	times	and	peak	area	of	 this	blank	 was	 calculated	 as	 noise	 level.	 The	 LOD	 was	calculated	as	three	times	the	noise	level.	
Table 9: LOD data for Guaifenesin and Dextrome-
thorphan 
S.no Sample name RT Area 
1 Guaifenesin 3.218 168283 
2 Dextromethorphan 4.071 58818 
Limit	of	quantitation	The	 sensitivity	 of	measurement	 of	 Guaifenesin	 and	Dextromethorphan	 by	 the	 use	 of	 proposed	method	was	estimated	in	terms	of	limit	of	quantitation	(LOQ).	The	LOQ	was	calculated	by	the	use	of	signal	to	noise	ratio.	 In	order	 to	estimate	 the	LOQ	value,	 the	blank	sample	was	 injected	 six	 times	and	 the	peak	area	of	this	blank	was	calculated	at	noise	level.	The	LOQ	was	calculated	as	ten	times	the	noise	value	gave	the	LOQ.	
Table 10: LOQ data for Guaifenesin and Dextrome-
thorphan 
S.no Sample name RT Area 
1 Guaifenesin 3.218 568444 
2 Dextromethorphan  4.070 197597 
Robustness	Effect	 of	 variation	 in	 flow	 rate:	 Prepare	 the	 system	suitability	solution	as	per	the	test	method	and	inject	into	 the	 HPLC	 system	 with	 ±0.2	 ml	 of	 the	 method	flow.	 Evaluate	 the	 system	 suitability	 values	 as	required	 by	 the	 test	 method	 for	 both	 flow	 rates.	Actual	flow	rate	was	1.0	ml/min	and	it	was	changed	to	 0.8ml/min	 and	 1.2ml/min	 and	 inject	 into	 HPLC	and	system	suitability	was	checked.	
Effect	 of	 variation	 in	 wavelength:	 Prepare	 the	system	suitability	solution	as	per	the	test	method	and	injected	 into	 the	 HPLC	 with	 ±2nm	 variation	 in	wavelength.	Evaluate	the	system	suitability	values	as	required	by	the	test	method	for	both	wavelengths.	
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Table 11: System suitability data of Guaifenesin and Dextromethorphan 
Parameter Guaifenesin Dextromethorphan Acceptance criteria 
Retention time 3.259 4.164  +-10 
Theoretical plates 7596 5595 >2500 
Tailing factor 1.45 1.53 <2.00 
% RSD 0.2 0.5 <2.00 
Table 12: Standard Results of Guaifenesin 
S.no Sampl name RT Area USP plate count USP tailing 
1. Injection1 3.255 3751177 7555 1.44 
2. Injection 2 3.256 3733409 7640 1.46 
3. Injection 3 3.254 3739270 7616 1.46 
4. Injection 4 3.252 3731263 7697 1.45 
5. Injection 5 3.250 3739890 7612 1.45 
Table 13: Standard Results of Dextromethorphan 
S.no Sample name RT Area USP plate count USP tailing 
1. Injection 1 4.157 1335256 5643 1.53 
2. Injection 2 4.153 1319961 5603 1.52 
3. Injection 3 4.149 1325705 5618 1.53 
4. Injection 4 4.142 1325466 5738 1.53 
5. Injection 5 4.138 1317842 5706 1.53 
Table 14: Specificity data for Guaifenesin and Dextromethorphan 
S no Sample name Guaifenesin area RT Dextromethorphan Area RT 
1 Standard 3726649 3.359 1341704 4.164 
2 Sample 3739051 3.250 1322868 4.134 
3 Blank - - - - 
4 Placebo - - - - 
 
Figure 5: Typical chromatogram of optimized method 
 
Figure 6: LOD data for Guaifenesin and Dextromethorphan  
 
Figure 7: LOQ data for Guaifenesin and Dextromethorphan 
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Table 15: Robustness data for Guaifenesin 
Parameter RT Theoreti-cal plates 
Tailing 
Factor 
Decreased flow 
rate(0.8ml/min) 4.034 8447 1.49 
Increased flow 
rate(1.2ml/min) 2.693 7155 1.46 
Decreased tempera-
ture(200c) 4.037 8570 1.49 
Increased tempera-
ture(300c) 2.701 7237 1.47 
Table 16: Robustness data for Dextromethorphan 
Parameter RT Theoreti-cal plates 
Tailing 
factor 
Decreased flow 
rate (0.8ml/min) 5.054 5355 1.56 
Increased flow rate 
(1.2ml/min) 3.404 5940 1.54 
Decreased temper-
ature (200c) 5.058 5451 1.56 
Increased tempera-
ture (300c) 3.437 6019 1.55 
CONCLUSION		The	 study	 is	 focused	 to	 develop	 and	 validate	HPLC	methods	 for	 estimation	 of	 Guaifenesin	 and	Dextromethorphan	in	tablet	dosage	form.	For	routine	analytical	purpose	it	is	desirable	to	establish	methods	capable	 of	 analyzing	 huge	 number	 of	 samples	 in	 a	short	time	period	with	good	robustness,	accuracy	and	precision	without	 any	prior	 separation	 steps.	HPLC	method	 generates	 large	 amount	 of	 quality	 data,	which	 serve	 as	 highly	 powerful	 and	 convenient	analytical	 tool.	 The	 method	 shows	 good	reproducibility	 and	 good	 recovery.	 From	 the	specificity	 studies,	 it	was	 found	 that	 the	 developed	methods	 were	 specific	 for	 Guaifenesin	 and	Dextromethorphan.		
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